|
[1] Denli A M, Tops B J, Plasterk R A, et al. Processing of primary microRNAs by the Microprocessor complex. Nature, 2004,432(7014):231-235.
[2] Ruvkun G. Molecular biology. Glimpses of a tiny RNA world. Science, 2001,294(5543):797-799.
[3] Sokilde R, Vincent M, Moller A K, et al. Efficient Identification of miRNAs for classification of tumor origin. Journal of Molecular Diagnostics, 2014,16(1):106-115.
[4] Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 2007,9(6):654-662.
[5] Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. Embo Molecular Medicine, 2011,3(8):495-503.
[6] Heneghan H M, Miller N, Lowery A J, et al. Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer. Annals of Surgery, 2010,251(3):499-505.
[7] Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clinical Chemistry, 2011,57(1):84-91.
[8] 胡俊庭, 鲍蕴文, 白艳, 等. 肺癌患者血清microRNA-21表达临床意义探讨. 中华肿瘤防治杂志, 2014,21(1):39-42. Hu J T, Bao Y W, Bai Y, et al.Serum microRNA-21 expression and its clinical significance in patients with lung cancer.Chinese Journal of Cancer Prevention and Treatment,2014,21(1):39-42.
[9] 叶敏华,叶鹏辉,张伟珠,等. 唾液与血浆微小RNA-21对早期食管癌的诊断价值. 南方医科大学学报, 2014,34(6):885-889. Ye M H, Ye P H, Zhang W Z, et al.Diagnostic values of salivary versus and plasma microRNA-21 for early esophageal cancer. Journal of Southern Medical University,2014,34(6):885-889.
[10] Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. International Journal of Cancer, 2010,127(1):118-126.
[11] Chen X, Hu Z, Wang W, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. International Journal of Cancer, 2012,130(7):1620-1628.
[12] Kota J, Chivukula R R, O'donnell K A, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009,137(6):1005-1017.
[13] Ji J, Shi J, Budhu A,et al. MicroRNA expression, survival, and response to interferon in liver cancer. New England Journal of Medicine, 2009,361(15):1437-1447.
[14] Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. European Journal of Cancer, 2011,47(5):784-791.
[15] Chen Z H, Zhang G L, Li H R, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate, 2012,72(13):1443-1452.
[16] Zhang C, Wang C, Chen X, et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clinical Chemistry, 2010,56(12):1871-1879.
[17] Porter-Gill P, Fu Y P, Kaushiva A, et al. Detection of bladder, breast and prostate cancer using serum and tissue miRNA profiling. Genome Biology, 2011,12(10):12-13.
[18] Suryawanshi S, Vlad A M, Lin H M,et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clinical Cancer Research, 2013,19(5):1213-1224.
[19] Zeng X, Xiang J, Wu M, et al. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. Plos One, 2012,7(10):102-111.
[20] Costinean S, Sandhu S K, Pedersen I M,et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of E mu-MiR-155 transgenic mice. Blood, 2009,114(7):1374-1382.
[21] Thai T H, Calado D P, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science, 2007,316(5824):604-608.
[22] Rodriguez A, Vigorito E, Clare S,et al. Requirement of bic/microRNA-155 for normal immune function. Science, 2007,316(5824):608-611.
[23] O'Connell R M, Kahn D, Gibson W S J, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity, 2010,33(4):607-619.
[24] Medina P P, Nolde M, Slack F J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 2010,467(7311):86-99.
[25] Hatley M E, Patrick D M, Garcia M R, et al. Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. Cancer Cell, 2010,18(3):282-293.
[26] Ma X, Kumar M, Choudhury S N, et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2011,108(25):10144-10149.
[27] Santanam U, Zanesi N, Efanov A, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proceedings of the National Academy of Sciences of the United States of America, 2010,107(27):12210-12215.
[28] Xiao C, Srinivasan L, Calado D P, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature Immunology, 2008,9(4):405-414.
[29] Ventura A, Young A G, Winslow M M,et al. Targeted deletion reveals essential and overlapping functions of the miR-17 similar to 92 family of miRNA clusters. Cell, 2008,132(5):875-886.
[30] Salerno E, Scaglione B J, Coffman F D, et al. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Molecular Cancer Therapeutics, 2009,8(9):2684-2692.
[31] Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and Its deletion leads to chronic lymphocytic leukemia. Cancer Cell, 2010,17(1):28-40.
[32] Boldin M P, Taganov K D, Rao D S,et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. Journal of Experimental Medicine, 2011,208(6):1189-1201.
[33] Kumar M S, Pester R E, Chen C Y,et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes & Development, 2009,23(23):2700-2704.
[34] Lambertz I, Nittner D, Mestdagh P, et al. Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo. Cell Death and Differentiation, 2010,17(4):633-641.
[35] Roush S, Slack F J. The let-7 family of microRNAs. Trends in Cell Biology, 2008,18(10):505-516.
[36] Trang P, Wiggins J F, Daige C L, et al. Systemic delivery of tumor suppressor microrna mimics using a neutral lipid emulsion inhibits lung tumors in mice. Molecular Therapy, 2011, 19(6): 1116-1122.
[37] Trang P, Medina P P, Wiggins J F,et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene, 2010,29(11):1580-1587.
[38] Lee S T, Chu K, Oh H J, et al. Let-7 microRNA inhibits the proliferation of human glioblastoma cells. Journal of Neuro-Oncology, 2011,102(1):19-24.
[39] Kent O A, Chivukula R R, Mullendore M, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes & Development, 2010,24(24):2754-2759.
[40] Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death and Differentiation, 2010,17(2):193-199.
[41] Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer, 2009,9(10):701-713.
[42] Misso G, Di Martino M T, De Rosa G, et al. Mir-34: A new weapon against cancer. Molecular Therapy-Nucleic Acids, 2014, 3(3): 195-206.
[43] Lanford R E, Hildebrandt-Eriksen E S, Petri A, et al. Therapeutic silencing of microrna-122 in primates with chronic hepatitis C virus infection. Science, 2010, 327(5962): 198-201.
[44] Su J, Baigude H, Mccarroll J, et al. Silencing microrna by interfering nanoparticles in mice. Nucleic Acids Research, 2011, 39(6):194-203.
[45] Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of micrornas in vivo with 'Antagomirs'. Nature, 2005, 438(7068): 685-689.
[46] Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of mir-10b inhibits metastasis in a mouse mammary tumor model. Nature Biotechnology, 2010, 28(4): 341-357.
[47] Jeon H M, Sohn Y W, Oh S Y, et al. Id4 imparts chemoresistance and cancer stemness to glioma cells by derepressing mir-9*-mediated suppression of Sox2. Cancer Research, 2011, 71(9): 3410-3421.
[48] Cittelly D M, Das P M, Salvo V A, et al. Oncogenic Her2 delta 16 suppresses mir-15a/16 and deregulates Bcl-2 to promote endocrine resistance of breast tumors. Carcinogenesis, 2010, 31(12): 2049-2057.
[49] Cittelly D M, Das P M, Spoelstra N S, et al. Downregulation of mir-342 is associated with tamoxifen resistant breast tumors. Molecular Cancer, 2010, 9(4): 317-326.
[50] Miller T E, Ghoshal K, Ramaswamy B, et al. Microrna-221/222 confers tamoxifen resistance in breast cancer by targeting p27kip1. Journal of Biological Chemistry, 2008, 283(44): 29897-29903.
[51] Cao M, Seike M, Soeno C, et al. Mir-23a regulates Tgf-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. International Journal of Oncology, 2012, 41(3): 869-875.
[52] Han S Y, Zhao M B, Zhuang G B, et al. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. Lung Cancer, 2012, 75(1): 30-37.
[53] Kastl L, Brown ISchofield A C. Mirna-34a Is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Research and Treatment, 2012, 131(2): 445-454.
[54] Sebio A, Pare L, Paez D, et al. The Lcs6 polymorphism in the binding site of let-7 microrna to the kras 3'-untranslated region: its role in the efficacy of anti-egfr-based therapy in metastatic colorectal cancer patients. Pharmacogenetics and Genomics, 2013, 23(3): 142-147.
[55] Chen F, Zhu H H, Zhou L F,et al. Inhibition of c-FLI Pexpression by miR-512-3 Pcontributes to Taxol-induced apoptosis in hepatocellular carcinoma cells. Oncology Reports, 2010,23(5):1457-1462.
[56] Shaham L, Binder V, Gefen N,et al. MiR-125 in normal and malignant hematopoiesis. Leukemia, 2012,26(9):2011-2018.
[57] Holleman A, Chung I, Olsen R R,et al. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene, 2011,30(43):4386-4398.
[58] Menendez P, Villarejo P, Padilla D,et al. Implications of the histological determination of microRNAs in the screening, diagnosis and prognosis of colorectal cancer. Journal of Surgical Oncology, 2013,108(1):70-73.
[59] Valeri N, Gasparini P, Braconi C, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proceedings of the National Academy of Sciences of the United States of America, 2010,107(49):21098-21103.
[60] Hong L, Han Y, Zhang Y,et al. MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opinion on Therapeutic Targets, 2013,17(9):1073-1080.
[61] 方楚玲,郭琳琅. miRNA对肺癌化疗耐药调控研究进展. 中华肿瘤防治杂志, 2014(1):72-76. Fang C L, Guo L L.Research situation of miRNAs in regulating chemotherapy resistance of lung cancer. Chinese Journal of Cancer Prevention and Treatment, 2014(1):72-76.
[62] Connelly C M, Uprety R, Hemphill J, et al. Spatiotemporal control of microRNA function using light-activated antagomirs. Molecular Biosystems, 2012,8(11):2987-2993.
[63] Tiram G, Scomparin A, Ofek P, et al. Interfering cancer with polymeric siRNA nanomedicines. Journal of Biomedical Nanotechnology, 2014,10(1):50-66.
[64] Esquela-Kerscher A, Trang P, Wiggins J F, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle, 2008,7(6):759-764.
[65] Pramanik D, Campbell N R, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Molecular Cancer Therapeutics, 2011,10(8):1470-1480.
[66] Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nature Medicine, 2011,17(2):211-U105.
[67] Zhang Y, Wang Z, Gemeinhart R A. Progress in microRNA delivery. Journal of Controlled Release, 2013,172(3):962-974.
[68] Arroyo J.D, Chevillet J R, Kroh E M, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proceedings of the National Academy of Sciences of the United States of America, 2011,108(12):5003-5008.
[69] Grimm D, Wang L, Lee J S, et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. Journal of Clinical Investigation, 2010,120(9):3106-3119.
|
